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Abstract 
Background: There are many health benefits since 31 years after the foundation of the NHS in Brazil especially 
the increase in life expectancy. However, family-income inequalities, insufficient funding, and suboptimal 
private sector–public sector collaboration are still areas for improvement. The efforts of Brazil to achieve 
universal health coverage (UHC) for medicines has resulted in increased public financing of medicines and their 
availability, reducing avoidable hospitalization and mortality. However, lack of access to medicines still 
remains. Due to historical reasons, pharmaceutical services organization in developing countries may have 
important differences from high-income countries. In some cases, developing countries finance and promote 
medicines access by using the public infrastructure of health care/medical units as dispensing sites and cover 
all costs of medicines dispensed. In contrast, many high-income countries use private community pharmacies 
and cover the costs of medicines dispensed plus a fee, which includes all logistic costs. In this study, we will 
undertake an economic evaluation to understand the funding needs of the Brazilian NHS to reduce inequalities 
in access to medicines though adopting a pharmaceutical services organization similar to that seen in many 
high-income countries with hiring/accrediting private pharmacies. Methods: We performed an economic 
evaluation of a model to provide access to medicines within public funds based on a decision tree model with 
two alternative scenarios: public pharmacies (NHS, state-owned facilities) versus private pharmacies (NHS, 
agreements). The analysis assumed the perspective of the NHS. We identified the types of resources consumed, 
the amount and costs in both scenarios. We also performed a budget impact forecast to estimate the incremental 
funding required to reduce inequalities in access to essential medicines in Brazil. Findings: The model without 
rebates for medicines estimated an incremental cost of US$3.1 billion US in purchasing power parity (DPPP) 
but with an increase in the average availability of medicines from 65% to 90% for citizens across the country 
irrespective of family income. This amount places the NHS in a very good position to negotiating extensive 
rebates without the need for external reference pricing for government purchases. Forecast scenarios above 35% 
rebates places the alternative of hiring private pharmacies as dominant. Higher rebate rates are feasible and may 
lead to savings of more than US$1.3 billion per year (30%). The impact of incremental funding is related to 
medicines access improvement of 25% in the second year when paying by dispensing fee. The estimate of the 
incremental budget in five years would be US$4.8 billion DPPP. We have yet to explore the potential reduction 
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in hospital and outpatient costs, as well as in lawsuits, with increased availability with the yearly expenses for 
these at US$9 billion and US$1.4 billion DPPP respectively in 2017. Interpretation: The results of the 
economic evaluation demonstrate potential savings for the NHS and society. Achieving UHC for medicines 
reduces household expenses with health costs, health litigation, outpatient care, hospitalization and mortality. 
An optimal private sector–public sector collaboration model with private community pharmacy accreditation is 
economically dominant with a feasible medicines prices negotiation. The results show the potential to improve 
access to medicines by 25% for all income classes. This is most beneficial to the poorest families, whose 
medicines account for 76% of their total health expenses, with potential savings of lives and public resources. 
1. Introduction 
Promoting access to cost-effective, safe and quality medicines is a priority of public health policies1. Medicines 
are consumer goods as well as essential products for health with a key position in economies and in health 
services. They can have a strong and progressive burden on families as a consequence of the increasing costs 
of available treatments including, for example, cancer medicines in the United States and other essential 
medicines in developing countries where the cost of medicines can account for 60% or more of total healthcare 
expenditures2,3. Longer life expectancy as a result of new medicines, a higher prevalence of chronic diseases, 
and typically higher prices for new medicines especially those for cancer and orphan diseases, all contribute to 
increases in pharmaceutical expenditures in recent years4,5,6,7,8. The higher prevalence of particularly chronic 
diseases puts pressure on public budgets to enhance access to medicines, including all essential medicines, 
exposing the weaknesses of how developing countries, like Brazil, fund and organize their services to distribute 
prescribed medicines to their citizens 9. 
Many high-income countries have promoted health care as a right as part of their efforts to achieve universal 
health coverage (UHC) for medicines 1. The strategies adopted by high-income countries to fund and organize 
pharmaceutical services can differ from developing countries. Having said this, there is no universal access to 
healthcare for all in the US versus for instance Western European countries despite the US spending 
substantially more on health care as a percentage of gross domestic product (GDP)5. Despite efforts across 
countries, access to medicines presents challenges for the public supply system in all countries, especially in 
developing countries. Medicines losses and shortages occur simultaneously with concerns with the quality of 
pharmaceuticals in several developing countries,10,11,12,13, representing critical inefficiencies of public services 
resulting in increased patient expenditures in many countries as well as litigation in some countries where health 
is a constitutional right14,15,16. 
Between 2001 and 2014, data from the World Bank showed a substantial increase in public and private health 
expenditures in many countries. In the Brazilian scenario, this data showed a five times increase in health 
expenditures17. However, despite this increased funding, there are still concerns with the availability of essential 
medicines in the public healthcare system with no more than 62% availability of medicines in 201415, although 
up from 47% in 200118. In addition, the lack of access to medicines in ambulatory care may increase treatment 
expenses for the national health systems as a result of unnecessary progression of diseases which may result in 
hospitalizations. 
Due to historical reasons, pharmaceutical service organization in developing countries can have important 
differences from high-income countries. In some cases, developing countries finance and promote medicines 
access by using the public infrastructure of health care/medical units as dispensing sites and cover the costs for 
each component up to the dispensing of the medicine to patients. This is seen for instance in Malaysia and sub-
Saharan Africa where care for patients in the public healthcare system is provide via primary healthcare centres 
or outpatient clinics which can cover the cost of medicines supplied 19,20,21,22,23. In contrast, high-income 
countries typically use private community pharmacies and cover the costs of the medicines dispensed plus a 
fee, which includes all logistic costs. In the public services model in Brazil, medicines are provided according 
to the level of care: basic component - medicines and supplies related to diseases treated in primary health care; 
and specialized component - medicines and supplies for more complex diseases and patients treated by 
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specialists in public and private outpatient services. In the case of specialty medicines, this lack of access can 
be particularly severe in developing countries as seen by the lack of biological medicines to treat patients with 
cancer and immunological diseases in Brazil, Central and Eastern European countries and sub-Saharan African 
countries 24,25,26,27,28,29. Some high-income countries are also now facing difficulties with financing new medicine 
with continuously increasing prices despite limited incremental benefits for many new medicines7,30,31. One 
issue that makes the model adopted by the NHS Brazil different from a number of other countries with UHC is 
that there is no limit on medicines expenditure by families, i.e. safety net. This is similar to for instance Italy 
and Scotland where there is no co-payment for any medicine prescribed and Sweden where there are no patient 
co-payments after an initial limited amount 32,33,34. Whilst the Brazilian Institute for Geography and Statistics 
(IBGE) real-world data shows annually the impact of medicine expenses among all income classes, the current 
theoretical and legal concept, based on constitutional provision, is that the NHS could not impose a co-payment 
for medicines or services35. The adoption or not of co-payment by patients in Brazil were addressed with the 
implementation of the NHS Federal program in 2003. The program hires private pharmacies and provides 
medicines with co-payments but offers a very short list of medicines, targeting mostly cardiovascular diseases 
and diabetes. 
Overall, the universal healthcare responsibility within countries including Brazil implies the obligation to 
provide health care using public resources as the primary source of funding. The methods of provision and 
payment used to achieve UHC may range from pure state services, amalgamation with public and private 
entities, as well as direct contracting of private providers or social organizations. Regardless of the type of 
organization and provision adopted, public or private contracted, it will be necessary to establish a system of 
payments. Whether the provider is public or private, the funding system should have metrics to remunerate the 
service provider (pharmacies) to cover their costs. Other factors are the need to balance economic incentives 
and avoid cost escalation, while at the same time promoting equitable access, delivering quality care and 
products, and ensuring citizens' satisfaction. The conceptual models for pharmaceuticals payment systems 
include: 
I. Payment for inputs /resources: all resources consumed to produce pharmaceutical services (HR, 
infrastructure, logistics, medicines, etc.); 
II. Process Payment: types of procedures and health care performed; 
III. Payment for Production: quantity and types of medicines supplied to patients; 
IV. Payment by affiliated population: number of people registered in the health region of the provider; 
V. Payment for Health Results: number of healthy or satisfied patients; 
As mentioned, high-income countries typically follow the pay-per-production model where payments and 
pharmaceutical logistics are fully outsourced. The co-payment and safety-net concept in which households pay 
up to a pre-set threshold for medicines over a period are adopted in many countries including Australia, Canada, 
Denmark, England, Germany, Norway, Portugal, Spain and Sweden36,37,38, with, as mentioned, some countries  
adhering to full, free access to reimbursed medicines39,40. 
In 2017, the NHS in Brazil provided 247 medicines for outpatient medical specialties. These medicines are 
important due to their epidemiological impact and/or the cost that they represent for families (Figure 1). 
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Figure 1 (Number of specialty medicines by therapeutic subgroup paid by the NHS. Source: self-elaboration, 
data available from the NHS41) 
 
Alternative strategies adopted by low and middle-income countries (LMICs) for public pharmaceutical supply 
include central medical stores, autonomous supply agencies, direct delivery systems to patients, and dispensing 
sites in medical centers/units. Consequently, there will be economic implications of the alternative scenario of 
the private sector–public sector collaboration model with private community pharmacy accredited by the NHS. 
Similarly to many developing countries, Brazil adopted a model for the organization, payment and logistic 
provision of medicines that was almost completely state-owned. The public sector, in the three levels of 
management (municipal, state and federal), adopted a model of payment for inputs/economic resources 
consumed. 
Table 1: Country income level and access to essential medicines 42 
Country income  
group 
Median reported access level 
(%) 
Minimum reported  
(%) 
Maximum reported 
(%) 
Low-income 60 10 93 
Middle-income 85 30 100 
 Brazil 1999   <50 - - 
 Brazil 200116 47 41 53 
 Brazil 201415 62 61 64 
High-income 100 98 100 
Note:* The data from Brazil refer to the mean and the values for minimum and maximum refer to the confidence interval (95%).  
The efforts of Brazil to achieve UHC for medicines resulted in increased public financing of medicines and their 
availability, ranging from <50 in 1999 to 62% in 2014 (Table 1), reducing avoidable hospitalization and 
mortality. However, the lack of access still remains in Brazil with still lower levels of access compared with 
other middle-income countries43. Health benefits that have accrued include an increase of 13.8 years in life 
expectancy since the inception of the NHS in Brazil 35. However, factors including inequalities in family income, 
insufficient financing and cooperation between private and public sectors are still issues that need improving as 
these can impact on the quality of life of the Brazilian population 16. 
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Consequently in this study, we will undertake an economic evaluation to understand the funding needs of the 
Brazilian NHS in a scenario of adopting a pharmaceutical services organization similar to that seen in many 
high-income countries, that is hiring/accrediting private pharmacies to provide medicines access with public 
funds. As a result, we will seek to appreciably improve access to medicines compared with the current situation. 
At the same time, keep to the concept of no limit on medicines expenditure among families as this is an important 
concept in Brazil. 
2. Methods 
2.1 Overview 
We performed an economic evaluation regarding the provision of medicines with public funds in two alternative 
scenarios: public pharmacies (NHS state-owned facilities) versus private pharmacies (NHS agreements). The 
analysis assumed the perspective of the NHS. We identified the types of resources consumed, and the amounts 
and value of each item from Brazilian government data sources41. All the monetary values were adjusted 
according to the purchasing power parity index of the World Bank17. 
2.2 Model of pharmaceutical services 
We developed a model to evaluate alternative pharmaceutical services organization to provide access to 
medicines within public healthcare systems (Figure 2). The decision-tree model used inputs from a 
pharmaceutical services organization in Brazil for the medicines and supplies for outpatient medical specialties. 
We considered effectiveness in terms of medicines access as it is one of the goals of NHS funding, with citizens 
in Brazil having a right to health. 
Litigation, direct expenses, hospitalizations and death can be the consequences of a lack of access to pertinent 
medicines that can be used to cure, prevent and / or reduce the progression of both infectious and non-infectious 
diseases. Due to the difficulty in measuring the probabilities for each drug - 247 in total - in relation to a given 
consequence, in our study we investigated and calculated the total cost of each of these outcomes (Figure 2) to 
provide insight into current expenditures for these items. 
Figure 2 - Model for economic evaluation between pharmaceutical service organization alternatives for 
medicines access, NHS public pharmacies versus NHS agreements with private pharmacies - OECD medicines 
access model. 
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2.3 Availability of data about outcomes: litigation, out-of-pocket expenses, hospitalizations and death 
In Brazil, NHS Federal expenditures on health litigation is mostly a result of citizens demanding medicines44,45. 
We performed a search of the Ministry of Health (MoH) website, available literature, and contacted the officers 
at the Department Juridical Affairs of the MoH responsible for providing NHS technical-juridical information 
in cases of health litigation to gain robust data on the current status of medicine litigation in Brazil. 
We obtained data on out-of-pocket expenses (household income and expenditures) on health and medicines 
from the National Survey by Household Sample (PNAD) for 201746 and from the last available dataset from 
Household Budgets Survey (POF) for the years 2008/200947 for urban and rural areas. 
We obtained data related to specialty care with outpatient and hospital admissions due to conditions potentially 
treatable or avoidable with the use of medicines from Brazilian NHS databases from the frequencies of 
outpatient and hospital admissions services and its costs (payments) for the period from January to December 
of 2017. Furthermore, we extracted from the National Mortality database (2017) the deaths from potentially 
preventable causes41. 
2.4 Resource use 
We identified the relevant costs incurred in providing medicines access for the current model of pharmaceutical 
services in Brazil. In the alternative scenario, all steps for procurement, logistics and dispensing would be under 
a hiring agreement between the community private pharmacies and the NHS. The reimbursement happens for 
each medicine dispensed. The costs related to the management of the program remain in the control of the NHS 
(public sector) are equivalent in both models (Figure 3). 
Insert Figure 3 - Costs incurred to provide medicines access for the developing country model of pharmaceutical 
services 
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2.5 Model inputs 
We performed a search of the available data in the MoH administrative databases to obtain details of the 
medicines dispensed and the amount paid in 2017 (monthly data) for the specialized component of 
pharmaceutical services. These medicines are of considerable importance because of either their 
epidemiological impact or their costs. Examples of such medicines include anti-TNF alphas for rheumatoid 
arthritis, insulins for diabetes, statins for cardiovascular diseases, antivirals for hepatitis and medicines for 
schizophrenia48,49,50,51,52. 
Due to lead times for procurement and logistics, we set the safety stocks in the public sector at four months, 
which we present as costs with immobilized assets accepting that this four months of safety stocks produces 
an opportunity cost. In LMICs where inflation and interest rates are usually higher than high-income countries, 
as seen in Brazil, there are rules recommending NHS managers to invest in low-risk funds when expenditures 
are not happening. Logistics operation costs are functions which include warehousing, inventory management, 
and transportation in bulk. In LMICs, this part of the logistic process may be executed using public facilities 
and public servants. To simplify the model, we considered that private companies hired by public administration 
would undertake bulk pharmaceutical logistics operations as is currently the case among the Ministry of Health 
and other large Departments of Health in the Brazilian States, which is also the situation in the State of Minas 
Gerais and Rio de Janeiro. In the logistic agreements made by these States and the Ministry of Health, the costs 
are usually established as a percentage of the volume of loads and their respective prices. We set the costs with 
losses due to obsolete medicines, those expiring, spoilage, wastage, and theft at five percent of the annual cost 
of the medicines purchased. This is because the information for pharmaceutical losses is currently uncertain 
both in public or private sectors. Consequently, we adopted a wide interval in the sensitivity analysis to assess 
these influences in the different scenarios. 
The scenario of private pharmacy hiring agreements for dispensing transfers the steps related to the 
procurement, logistics operations and dispensing to the private sector. The NHS pays private pharmacies for 
access to each drug dispensed and must cover the cost of outsourced steps. The economic risks of these 
operations are implicit and under the responsibility of the private sector. All the parameters as a result of the 
literature searches, NHS databases, surveys of government websites and information provided by public 
authorities adopted as model inputs, are summarized in Table 2. 
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Table 2 - Parameters, base value and intervals adopted as model inputs for pharmaceutical dispensing services 
NHS 
 Parameters n 
Costs 
USD$PPP 
Interval Total Source 
 Medicines purchased by NHS 244 NHS Data *  39 
 Medicines costs private pharmacies 244 PMVG 0% **  50 
D
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Salaries and wages expenses1      
Pharmacists, monthly salary 9 5,000 3,192 - 8,865 45,008 52 
Attendants, monthly salary 92 2,268 1,570 – 4,015 208,647 52 
Facilities structure expenses      
Operation services hours 
12h/day; 
5days/week; 
22days/month 
   Survey 
Rent/property (real state value, m2) 1 60 54 – 65 60 51 
Depreciation rate (equipment’s, 5%) 1 172,467 155,220 – 189,713 172,467 53 
Utilities (telecom, energy, water) 1 25,000 22,500 – 27,500 25,000 53 
Security, cleaning services and supplies 1 15,000.00 13,500 – 16,500 15,000 53 
Office supplies 1 10,000 9,000 – 11,000 10,000 53 
Number of dispensing per month 44.000  11.000 – 88.000  53 
Number of medicines per patient 2.4  1.3 – 3.8  54,55,56 
 Costs immobilized assets 0.0971  0.0620 – 0.1373  Survey 
 Logistics operation costs 4%  2 – 6%   
 Costs with losses 
5% annual 
volume handled 
 2 – 40%  53 
 Costs with potential frauds in reimbursement 2%  0,5 - 5%  57 
B
en
ef
it
s Medicines availability NHS 65%  55 – 75%     18 ,55 
Medicines availability Private Pharmacies 90%  85-95%     18, 58 
Notes:  
*Consulted data from the acquisitions made in NHS during the year 2017  
**The reference value: defined as the value of the brand at the 1st decile price, for government purchases without taxes (PMVG 0%, CMED) 
 
  
2.6 Dispensing and maintenance costs of public pharmacies by NHS 
To develop the model, we considered public pharmacy operation hours as twelve hours of service per day, five 
days a week and twenty-two days a month. To establish these values, we surveyed the webpages of the twenty-
seven Brazilian States of the NHS pharmaceutical dispensing services. For public-employees, we considered 
eight hours per day and forty hours per week. This is because the NHS State pharmacies, which have the 
responsibility for dispensing specialty medicines, do not open on Saturdays and Sundays. We obtained the 
number of medicines dispensed per month, and the other values of production of a typical public pharmacy for 
specialty medicines, in the NHS databases in the State of Minas Gerais. The costs related to the real estate were 
valued based on the cost per m2 for renting from the national index of economic research54. The values of the 
public employees’ salaries for Brazil were obtained from market signals research station – EPSM55. 
The average monthly costs of dispensing and maintaining an NHS public pharmacy is the result of the sum of 
all the resources spent on producing the service divided by the number of dispensing per month: 
𝐴𝑣𝑒𝑟𝑎𝑔𝑒 𝐶𝑜𝑠𝑡 𝑝𝑒𝑟 𝐷𝑖𝑠𝑝𝑒𝑛𝑠𝑖𝑛𝑔 =
 𝑅𝑒𝑠𝑜𝑢𝑟𝑐𝑒𝑠 𝐶𝑜𝑛𝑠𝑢𝑚𝑒𝑑
𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑑𝑖𝑠𝑝𝑒𝑛𝑠𝑎𝑡𝑖𝑜𝑛 𝑟𝑒𝑎𝑙𝑖𝑧𝑒𝑑 𝑖𝑛 30 𝑑𝑎𝑦𝑠
 
2.7 Unit cost of medicines purchased by NHS 
We retrieved the unit cost of the specialty medicines provided by NHS from the official databank of medicines 
procurement for the year of 201762. This is the real-world prices for the NHS as Brazilian public health 
authorities cannot currently make confidential price agreements under the law. 
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2.8 Unit cost of medicines in the private pharmacies 
In Brazil, the National Pharmaceutical Market Authority (CMED) regulates the maximum prices for 
government and consumer purchases. This data is updated monthly by CMED and made available for the public 
consultation on the government website53. Using this information, we created a database with all prices for all 
the brands available for the specialty medicines. We used the prices list released by CMED for September 2018. 
We extracted the unit cost of each specialty medicine from the database created for all brands available in the 
Brazilian market for the selected medicines. The unit cost for private community pharmacies has been defined 
as the maximum medicine price for the government purchases (PMVG) situated in the first decile of all brands 
available. We inputted in the model parameters for potential market prices for NHS payment in the private 
pharmacies using the following rational that was previously adopted by the Ministry of Health initiative called 
“Aqui Tem Farmácia Popular do Brasil”: 
o Minimum value - cheapest brand between all medicines in the market for each drug;  
o Base value - brand price in the first decile of all medicines in the market for each drug;  
o Maximum value - brand price in the median of all medicines for each drug 
2.9 Monthly treatment cost 
We estimated the monthly costs for each medicine by multiplying the unit cost by the number of pharmaceutical 
units required for a monthly treatment (30 days). For these estimates, we considered the number of 
pharmaceutical units needed for each treatment based on Defined Daily Doses (DDD) from the WHO 
Collaborating Centre for Drug Statistics Methodology63. The DDD is the assumed average maintenance dose 
per day for a drug used for its main indication in adults. In case information was not available in the ATC/DDD 
system, the maximum amounts permitted and authorized by the Ministry of Health for dispensing, according to 
the main indication recommend in the Clinical Protocols and Therapeutic Guidelines adopted in the NHS, was 
used to calculate the DDDs64. 
We added to the monthly treatment costs the sum of the dispensing and maintenance costs in the public 
pharmacies, the logistic operation costs, and any losses per month. In the private model, the monthly treatment 
cost additionally included the percentage costs with losses from potential frauds in reimbursement as stated in 
audit reports (Figure 3). 
2.10 Potential Benefits 
The increase in the availability of medicines incorporated routinely into the Brazilian NHS should help reduce 
litigation and out-of-pocket expenses as well as subsequent hospitalizations and deaths (outcomes). The 
medicines access research reports (2004 and 2017) showed a 62% availability of medicines while in the private 
pharmacies this was approximately 90%. We assumed an access rate in public pharmacies of 65%, ranging from 
55 to 75%. For the private model, we assume 90% access, ranging from 85% to 95%. 
2.11 Sensitivity analysis 
We performed a sensitivity analysis to test uncertainties arising from the model inputs. As the first step, we 
tested univariate variables to assess how the results might change. After testing each parameter individually, we 
evaluated the impact on results through probabilistic sensitivity analysis using Monte Carlo simulation. 
Results 
NHS distributed approximately 21.4 million treatments in Brazil in 2017, spending eight billion dollars. 
Examples include immunosuppressant for rheumatoid arthritis, statins for cardiovascular diseases, antivirals for 
hepatitis and mental health medicines used for schizophrenia (Figure 4). 
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Figure 4 - (Number of estimated treatments for each medicine provided by therapeutic subgroup, NHS, Brazil 
2017 (Source: self-elaboration, data available from NHS41) 
 
The model estimated an incremental cost of US$3.1 billion (DPPP) in a scenario of no rebates over medicine 
reference prices for government purchases (PMVG), but with an increase in the average availability of 
medicines from 65% to 90% for citizens across the country and for all classes of family incomes (Table 2 and 
Figure 5). The scenarios above 35% rebates put the alternative of hiring private pharmacies as dominant. Higher 
rebates are feasible and may lead to savings of US$1.3 billion (DPPP) per year (Figure 5 and Table 3). 
Insert Figure 5 - Costs and rebates rates on the comparative PMVG between public and private pharmacies 
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Table 3: Forecast incremental cost in different rebate scenarios for distribution of medicines in private 
pharmacies 
Strategy 
Cost 
(Billions US$PPP) 
Incremental Cost 
(Billions US$PPP) 
Forecast scenario: no rebate   
Public Pharmacy (State-owned facilities) 5,711,682,916.31  
Private pharmacy (NHS agreements) 8,812,681,695.98 3,100,998,779.67 
Forecast scenario: rebate 30%   
Public Pharmacy (State-owned facilities) 5,711,682,916.31  
Private pharmacy (NHS agreements) 6,168,877,187.19 457,194,270.88 
Forecast scenario: rebate 50%   
Public Pharmacy (State-owned facilities) 5,711,682,916.31  
Private pharmacy (NHS agreements) 4,406,340,847.99 (- 1,305,342,068.32) 
   
Funding demanded to achieve universal health coverage 
To understand the funding demanded to achieve UHC for medicines, we analyzed the budget impact forecast 
scenario with 35.19% rebates over first decile brand prices. In this scenario, we may see the estimated cost of 
hiring private community pharmacies. We estimate the incremental budget, considering that between the first 
and second year there would be a further 25% increase in access in the scenario of the NHS choosing to hire 
private pharmacies. The budget impact for the NHS would increase at a rate of 6% after that, which is the 
average growth of the last decade of the dispensing of these medicines in the NHS (Table 4). The impact of 
incremental funding is related with the access gain of 25% (second year) to move from payment for inputs of 
public dispensing to the private pharmacies contracting, and the incremental budget in five years would be 
US$4.8 billion DPPP. We have yet to explore what would be the reduction in hospital/outpatient costs and 
lawsuits, with the yearly expenses for the NHS at US$9 billion and US$1.4 billion DPPP, respectively in 2017. 
Table 4: Funding demanded to achieve universal health coverage for medicines presented as budget impact 
analysis, estimate for five years forecast scenario with 35.19% rebates*. 
Year 
Treatments Access Growth Budget Estimate Impact  Budget Estimate Impact 
Public                      Private (%) Public Pharmacies Private Pharmacies b 
1 21,881,719.30 21,881,719.30 base year 5,711,682,916.31 5,711,683,192.33 
2 23,174,852.21 27,352,149.13 25a+6 6,049,223,355.86 7,139,603,991.57 
3 24,544,404.75 28,968,565.26 6 6,406,711,254.25 7,561,529,559.43 
4 25,994,893.03 30,680,505.93 6 6,785,325,430.57 8,008,389,452.70 
5 27,531,100.10 32,493,616.29 6 7,186,314,382.00 8,481,657,198.57 
Incremental Access 18,249,586.52 Incremental Budget 4,763,606,055.61 
Notes: (a) 25% is the incremental access between expected availability scenario of hiring private pharmacies (b) The reference value: defined as the value of the brand at the 
1st decile price, for government purchases without taxes (PMVG 0%, CMED), with a rebate rate of 35.19%. 
 
Sensitivity analysis 
We perform the univariate sensitivity analysis on the variables with uncertainty and potential impact on the 
results. These included the monthly salary of pharmacists, the number of pharmacists per pharmacy, the number 
of medicines dispensed per month, the average number of medicines prescribed per patient, the unit cost of 
medicines, as well as the cost associated with logistic losses and losses due to reimbursement (Table 5). 
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Table 5: Univariate sensitivity analysis of the parameters 
 
Parameter Base value Interval 
Variation of incremental cost 
(PPP$) 
P
u
b
li
c 
P
h
a
rm
a
c
ie
s 
Monthly cost of pharmacist (salary, US$PPP) 5,000.83 
3,191.48 
8,865.24 
3,104,313,696.20 
3,093,918,801.60 
Number of pharmacists per pharmacy 9 
1 
16 
3,109,142,800.33 
3,093,872,761.60 
Number of dispensing per month 44.000 
11.000 
88.000 
2,902,559,701.36 
3,134,071,959.39 
Number of medicines per patient 2.4 
1.3 
3.8 
3,045,028,783.23 
3,125,368,491.05 
Costs with losses 1.05 
1.02 
1.4 
3,257,656,501.96 
1,273,325,352.95 
B
o
th
 
Coefficient of variation of the Unit Cost 1 
0.35 
1.65 
1,042,354,439.25 
5,159,643,120.10 
P
r
iv
a
te
 
P
h
a
rm
a
c
ie
s 
Costs with potential frauds in reimbursement 1.02 
1.005 
1.05 
2,984,393,133.56 
3,334,210,071.90 
 
    
The sensitive analysis scenarios demonstrated that the two most important parameters that might affect the 
incremental costs are the coefficient of variation of the unit costs and the cost associated with losses. Increased 
logistic efficiency of the NHS, with reduced losses, raises the incremental cost to hire private pharmacies by 
5.1%. 
Nevertheless, in a scenario of lack of control and increased losses, the incremental cost to hire private 
pharmacies would reduce by 58.9%. In a scenario of reduced unit costs by 65%, with a larger share of 
generic/similar medicines, for example, there would be a reduction of the incremental cost to hire private 
pharmacies by 66.4%. Whereas if there is an increase in the average unit cost due to lower supply/share of 
generic/similar medicines, this may produce an increase in the incremental costs to hire private pharmacies by 
66.4%. 
Model limitations 
Understanding that the lack of medicine access may have consequences including litigation, out-of-pocket 
expenses, hospitalizations, and death, we designed an ideal model to try and incorporate these parameters. 
However, the probabilities for each of 247 specialty drugs provided by the NHS in 2017 for these four 
consequences are difficult to measure. Consequently, in our study, we just investigated the total cost for each 
of these outcomes once the expenses for the NHS and families are linked to the lack of access, excluding 
premature deaths (Figure 6). 
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Figure 6: Ideal Model for economic evaluation between pharmaceutical service organization alternatives for 
medicines access, NHS public pharmacies versus NHS agreements with private pharmacies. 
 
Potential Benefits 
Data from the Family Budget Survey (POF) showed that the poorest Brazilian families medicines’ expenditure 
was 66.5% of their total health spending47,48. The POF registered important differences between the distributions 
of household expenditures with healthcare and medicines concerning the family income distribution of the 
Brazilian population by total income class (Figure 7)66. The data shows that the lower the income, the higher 
the impact of spending on medicines as a percentage of total family expenses on health. The poorest families, 
which represent 22.5% of the country, have a burden of more than 76% of their expenses on medicines in 
relation to their total health care costs, while in the upper levels of the Brazilian society this reduces to 34%. 
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Figure 7 - Distribution of the household expenses with health care and medicines by class of total income in 
Brazil (2009) 65 
 
The combined scenario of low availability of medicines and economic distress related to health expenses can 
lead to litigation against the NHS. As previously mentioned, in Brazil, NHS Federal expenditures on litigation 
are mostly due to citizens demanding medicines, corresponding to approximately 80% of the total lawsuits. In 
dollar amounts, as mentioned, the NHS currently spends approximately US$1.4 billion (DPPP) per year on 
litigation. This is in addition to the costs associated with regular administrative claims for medicines received 
by the NHS45.  
In 2017, data from DATASUS indicate that the NHS in Brazil paid for more than 2.3 million hospital admissions 
and 5.6 million outpatient care procedures associated with procedures and complications potentially related to 
the treatments for which clinical protocols in the NHS exist. The care provided by the NHS for these procedures, 
as mentioned, costs approximately US$9 billion DPPP in 2017 (Figure 8). The most demanded treatments were 
related to kidney problems, cardiovascular disease, infections and psychiatric treatment, for which there are 
medicines listed by the NHS for the control and a reduction in the worsening of the clinical conditions. 
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Figure 8 - Costs of the NHS with outpatient and hospital procedures in Brazil (2017) 
 
The last year with available data for mortality is 2016. The number of deaths from potentially preventable 
causes, including adequate clinical management and medicines usage, was more than 100,000 cases (Figure 9). 
Deaths related to hepatic, renal, cardiovascular and infection problems were highlighted, and most of these 
clinical conditions are treatable and/or preventable with medicines incorporated in the Brazilian NHS, which 
should be readily available. 
Figure 9: (Mortality due to avoidable causes in Brazil (2016) 
 
Proposed private sector–public sector collaboration for pharmaceutical services organization 
The optimal private sector–public sector collaboration looks to be the key to achieving UHC for medicines 
reducing subsequent avoidable hospitalization and mortality as well inequalities among families concerning 
household expenses. The resultant services organization (Figure 10) might consider the use of an information 
system and a simple workflow. It is important to preserve some of the NHS advantages of having the citizens 
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geographically referred to the public health services centers in their neighborhood. The available health centers 
provide medical care, prescriptions and authorization to obtain medicines in a private pharmacy of the citizen’s 
choice. Pharmacists and pharmacies should work under the same information system and send invoices for 
payment to the appropriate government agency as typically happens in high income countries. The authorization 
system of the NHS would validate and reimburse the medicines (Figure 10). 
Figure 10: NHS services model to provide access to medicines, private pharmacies agreements 
 
4. Discussion and conclusions 
Despite important advances made in the implementation and improvement of NHS in Brazil, access to 
medicines remains a focus of inequality and health litigation. Insufficient progress though has been made about 
the direct disbursement of the poorest families with pharmaceutical products over the years. 
The total value of medicines purchased annually by the NHS should though place it in a position of obtaining 
appreciable rebates. The scenarios above 35% rebates put the alternative of hiring private pharmacies as 
dominant but higher rebates are feasible and may lead to savings of US$1.3 billion per year (DPPP) (Figure 5 
and Table 3). This study does not recommend the adoption of reference pricing for government purchases 
(PMVG with 0% tax) as a basis for NHS payment for dispensing. This is according to data from the Union of 
the Pharmaceutical Manufacturer Companies67 which state that in the Brazilian pharmaceutical market there is 
an average rebate of 41% over the unit cost of medicines. This can potentially be higher with more aggressive 
purchasing approaches. Reference pricing may reduce the size of the rebate alongside other concerns with 
reference pricing including appropriate comparator countries and their economic considerations including GDP 
67,68. There are also issues of transparency with reference pricing since list prices within countries typically not 
including confidential discounts, which are now a key element of pricing negotiations for medicines across 
countries 69,70,71,72.  
Preventable morbidity and mortality due to a lack of access to medicines affects developing countries economies 
such as Brazil. In addition to the social and economic consequences, the inefficiency of the model adopted leads 
to productivity loss for families, especially low-income families who are affected by economic crises and 
usually have to accept working conditions not protected by social security or labor legislation. It is possible that 
the consequences of this potentially preventable morbidity and mortality affect the economy as a whole. The 
seriousness of this framework implies an increase in costs for the NHS itself due to clinical complications and, 
finally, loss of quality of life for the citizens. It would be worth pointing out that the loss of citizens' quality of 
life alone would be reason enough to justify the improvement of public health policies and the reduction of 
inequality in access to medicines in the country.  
As mentioned, the economic advantage in the private model occurs with a rebate rate of 35%. The new model 
proposal (Figure 10) considers the use of an information system and a simple workflow. Citizens would still be 
referred to their health territory where they may receive medical care, prescriptions and authorization to obtain 
prescribed medicines in the private pharmacy of their choice. Pharmacies would send the invoice for payment 
to the appropriate government agency. The authorization system of the NHS would subsequently validate and 
reimburse the medicines. 
This is a peer-reviewed, accepted author manuscript of the following article: Garcia, M. M., Azevedo, P. S., Mirelman, A., Safatle, L. 
P., Iunes, R., Bennie, M. C., ... Guerra Junior, A. A. (Accepted/In press). Funding and service organization to achieve universal health 
coverage for medicines: an economic evaluation of the best investment and services organization for the Brazilian scenario. Frontiers 
in Pharmacology , 1-21. https://doi.org/10.3389/fphar.2020.00370 
 
18 
 
The implementation studies necessary to change the actual service models to provide access to medicines is 
complex and the success or not will rely on the strategies adopted. This implementation phase will demand 
specific studies which were not the focus of this paper. Overall, we believe the results of this economic 
evaluation robustly demonstrate the benefits with the introduction of an optimal model of collaboration between 
public-private sectors. The current model of pharmaceutical services provided by NHS Brazil produces 
inequality, shortages of medicines especially for chronic diseases, and jeopardizes other health policies and 
household income. The model used in many high-income countries with accredited private community 
pharmacies appears more economical alongside competent price negotiations for medicines which we believe 
is feasible. The results also suggest that the inclusion of private community pharmacies in NHS has the potential 
for improving access to medicines by 25% across all income classes with the greatest benefit to the poorest 
families.  
Overall, we believe that the results presented in this article can result in new health policies and help to reduce 
inequalities in access to medicines in Brazil, with potential savings in lives and public resources through the 
negotiation of prices practiced in the Brazilian market. In addition, the study helps support decision making by 
managers by allowing them to evaluate different scenarios within the Brazilian context. We will be monitoring 
these developments in the future. 
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